Factor D Inhibitors for Complement Pathway Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement pathway, such as age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, and rheumatoid arthritis, lack effective small molecule inhibitors for Factor D, which is crucial in the alternative complement pathway, leading to inadequate control of inflammatory responses and cellular damage.
Innovation Solution
Development of specific compounds, as outlined in Formula I and their pharmaceutically acceptable salts, to inhibit Factor D activity, thereby modulating the complement pathway and reducing detrimental inflammatory responses in disorders associated with the alternative, classical, and lectin pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement pathway disorders are used, then existing therapeutic options are available, but effective small molecule inhibitors for Factor D are lacking, leading to inadequate control of inflammatory responses
Solution Approach 1:
The patent segments the complement pathway into specific targetable components, focusing on Factor D as a discrete inhibitable element. By developing compounds that specifically bind to and inhibit Factor D protease activity, the invention isolates and addresses the specific deficiency in current treatments rather than using broad-spectrum approaches.
Solution Approach 2:
The invention changes the therapeutic parameter from available but ineffective treatments to novel small molecule inhibitors with specific biochemical activity against Factor D. The compounds are designed to alter the enzymatic activity parameters of Factor D, providing a new mechanism of action that was previously unavailable.
2Object-affected harmful factors
If Factor D activity is not inhibited, then the complement pathway continues to function, but detrimental inflammatory responses and cellular damage occur in disorders like AMD, PNH, and rheumatoid arthritis
Solution Approach 1:
The patent applies preliminary anti-action by inhibiting Factor D before the complement cascade can generate harmful inflammatory mediators. The small molecule compounds prevent the formation of C3 convertase, thereby blocking the downstream production of C3a and C5a anaphylatoxins before they can cause tissue damage in disorders like AMD, PNH, and rheumatoid arthritis.
Solution Approach 2:
The invention converts the harmful overactivation of the alternative complement pathway into a beneficial therapeutic effect by selectively inhibiting Factor D. This targeted inhibition transforms the pathological complement cascade into a controlled state, reducing inflammatory damage while preserving necessary immune functions.
3Adaptability or versatility
If novel Factor D inhibitors are developed, then unmet needs in treating PNH and other complement-mediated disorders are addressed, but current treatments like eculizumab require life-long intravenous injections and many patients remain anemic
Solution Approach 1:
The patent substitutes the mechanical delivery system of intravenous injections with orally bioavailable small molecule compounds. The novel Factor D inhibitors are designed to be administered via oral or other non-invasive routes, replacing the cumbersome intravenous injection mechanism required by current treatments like eculizumab.
Solution Approach 2:
The invention changes the pharmacokinetic parameters of complement pathway inhibition from parenteral administration to oral availability. The small molecule compounds are designed with improved bioavailability and half-life characteristics, enabling less frequent dosing and eliminating the need for lifelong intravenous access and monitoring.
Data Source
AI summary
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.